Cambridge Investment Research Advisors
GH icon

Cambridge Investment Research Advisors’s Guardant Health GH Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Sell
9,029
-2,034
-18% -$221K ﹤0.01% 2015
2026
Q1 		$1.02M Buy
11,063
+218
+2% +$21.9K ﹤0.01% 2150
2025
Q4 		$1.11M Sell
10,845
-136
-1% -$12.2K ﹤0.01% 2015
2025
Q3 		$686K Sell
10,981
-1,258
-10% -$68.4K ﹤0.01% 2373
2025
Q2 		$637K Sell
12,239
-315
-3% -$14.1K ﹤0.01% 2324
2025
Q1 		$535K Sell
12,554
-4,043
-24% -$174K ﹤0.01% 2374
2024
Q4 		$507K Buy
16,597
+6,769
+69% +$190K ﹤0.01% 2419
2024
Q3 		$225K Buy
9,828
+41
+0.4% +$1.16K ﹤0.01% 3051
2024
Q2 		$283K Sell
9,787
-16,692
-63% -$389K ﹤0.01% 2746
2024
Q1 		$546K Buy
26,479
+1,641
+7% +$35.2K ﹤0.01% 2210
2023
Q4 		$672K Sell
24,838
-846
-3% -$22.2K ﹤0.01% 1950
2023
Q3 		$761K Buy
25,684
+11,498
+81% +$404K ﹤0.01% 1751
2023
Q2 		$508K Sell
14,186
-393
-3% -$11.3K ﹤0.01% 2125
2023
Q1 		$342K Buy
14,579
+6,464
+80% +$185K ﹤0.01% 2370
2022
Q4 		$221K Buy
8,115
+2,074
+34% +$94.9K ﹤0.01% 2670
2022
Q3 		$325K Buy
+6,041
New +$310K ﹤0.01% 2298
2022
Q1 		– Sell
-2,860
Closed -$286K – 3218
2021
Q4 		$286K Sell
2,860
-2,014
-41% -$208K ﹤0.01% 2566
2021
Q3 		$609K Buy
4,874
+136
+3% +$16.2K ﹤0.01% 1897
2021
Q2 		$588K Sell
4,738
-3,574
-43% -$481K ﹤0.01% 1927
2021
Q1 		$1.27M Sell
8,312
-7,741
-48% -$1.17M 0.01% 1271
2020
Q4 		$2.07M Buy
16,053
+7,639
+91% +$879K 0.01% 907
2020
Q3 		$941K Buy
8,414
+2,720
+48% +$249K 0.01% 1224
2020
Q2 		$462K Buy
5,694
+725
+15% +$58.4K ﹤0.01% 1600
2020
Q1 		$346K Sell
4,969
-58
-1% -$4.45K ﹤0.01% 1592
2019
Q4 		$393K Buy
5,027
+806
+19% +$58.1K ﹤0.01% 1738
2019
Q3 		$269K Buy
+4,221
New +$372K ﹤0.01% 1907
2019
Q2 		– Sell
-3,070
Closed -$235K – 2258
2019
Q1 		$235K Buy
+3,070
New +$170K ﹤0.01% 1964

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cambridge Investment Research Advisors's GH Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Guardant Health (GH) stake by 18% in Q2 2026, selling an estimated $221K and leaving 9,029 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Cambridge Investment Research Advisors first reported a position in GH in Q1 2019 and has held it in 27 quarters since. The position peaked at $2.07M in Q4 2020. 601 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • Cambridge Investment Research Advisors held 9,029 shares of Guardant Health worth $1.35M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 2,034 Guardant Health shares in Q2 2026, an estimated $221K.
  • Guardant Health made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2015 holding.
  • Cambridge Investment Research Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 27 quarters since.
  • Cambridge Investment Research Advisors's Guardant Health position peaked at $2.07M in Q4 2020.
  • 601 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.